27.05.2020 • 13:30 - 15:00 • Symposien

Rahmenbedingungen

Is biotech green enough for green investment?

Sustainable investments with funds are on a growth course. For example, the EIB is phasing out the funding of infrastructure and facilities for fossil fuels. However, there is no uniform definition or universal standard for ethical-ecological – or “sustainable” “green” or “climate-friendly” – investments. The most important features in the search for a sustainability fund are e.g. exclusion criteria for manufacturers of military equipment and genetically modified plants. Biotechnology in general can make a significant contribution to achieving the sustainability goals of the United Nations, but is not considered sustainable for investment purposes. When is biotech green enough for green investment?

Moderation

Dr. Holger Bengs BCNP Consultants GmbH

Impulsvortrag

Kristina Jeromin Deutsche Börse

Kristina Jeromin joined Deutsche Börse Group in 2009 and was initially responsible for the internal and external communication of the Group-wide sustainability strategy. Since 2015, she is responsible as Head of Group Sustainability for group-wide sustainability management, covering the company’s roles as an international capital market organiser and DAX-listed company. Kristina is since 2018 Managing Director of the Green and Sustainable Finance Cluster Germany, member of the board at econsense – Forum for Sustainable Development of German Business e.V. and member of the German Society of the Club of Rome. Kristina is a deputy chairwoman of the German government's Sustainable Finance Advisory Board.

Podium

Kristina Jeromin Deutsche Börse

Kristina Jeromin joined Deutsche Börse Group in 2009 and was initially responsible for the internal and external communication of the Group-wide sustainability strategy. Since 2015, she is responsible as Head of Group Sustainability for group-wide sustainability management, covering the company’s roles as an international capital market organiser and DAX-listed company. Kristina is since 2018 Managing Director of the Green and Sustainable Finance Cluster Germany, member of the board at econsense – Forum for Sustainable Development of German Business e.V. and member of the German Society of the Club of Rome. Kristina is a deputy chairwoman of the German government's Sustainable Finance Advisory Board.

Michael Krel Sofinnova Partners

Michael joined Sofinnova as Senior Associate in 2013 and has been involved ever since in the investment activity of Sofinnova in industrial biotech. He focuses on early stage deals in Europe and North America with applications in chemicals, materials, agriculture, food, feed and synthetic biology. He sits as an observer on Comet Bio board and sits on the boards of EnobraQ and Afyren. He has been the CEO of EnobraQ (a Sofinnova green Seed Fund portfolio company) for 2 years, and has transitioned out of the company to focus on investments. Prior to Sofinnova, Michael spent six years in Industrial biotech start-ups, holding business development positions.  After completing his PhD studies, Michael was a consultant focused on R&D’s strategic and organizational issues. Michael is a graduate engineer from Ecole Polytechnique and holds a PhD in organic chemistry from Paris X Orsay University.

Dr. Martin Langer BRAIN AG

Dr. Martin Langer, Jahrgang 1965, studierte zwischen 1986 und 1992 Biologie an der TU Darmstadt sowie der Flinders University in Adelaide. Im Zuge seiner Promotion forschte er zwischen 1992 und 1995 an der Universität Karlsruhe an der Aufklärung von enzymatischen Wirkprinzipien. Anfang 1995 trat er bei BRAIN als Projektleiter ein und engagierte sich zunächst in der GMP-Prozessentwicklung von rekombinanten Proteinwirkstoffen und der Bio-Analytik.

Von 2000 bis 2005 war er in einem Tochterunternehmen der BRAIN mit Pharma-Biotech-Schwerpunkt für das Business Development verantwortlich und gestaltete in dieser Zeit einige Finanzierungsrunden des Start-Ups mit Private Equity und klassischem Venture Capital mit.

Mitte 2005 übernahm er bei BRAIN die Leitung der Unit Corporate Development. Hier verantwortet er neben Marketing und Kommunikation auch die Unternehmens-entwicklung und -strategie. Im Januar 2013 wurde Dr. Langer als Mitglied der Geschäftsleitung der BRAIN AG berufen. Zum Juli 2015 wurde er zum Executive Vice President Corporate Development und Prokuristen des Unternehmens berufen. 2015/16 war er der verantwortliche Projektleiter, der den erfolgreichen Börsengang der BRAIN am Prime Standard der Frankfurter Wertpapierbörse vorbereitete. Er begleitete zum IPO zahlreiche Roadshows zu internationalen Investoren. Von 2016 bis 2019 war er auch für Investor Relations der BRAIN verantwortlich. Seit 2019 leitet Dr. Langer das operative Geschäft in der BRAIN Business Unit Industrial BioSolutions.

Go back